Targeted Therapies for Metastatic Esophagogastric Cancer
Targeted Therapies for Metastatic Esophagogastric Cancer
复制标题
DOI：
10.1007/s11864-011-0138-4
复制
发表时间：
2011-03-01
影响因子：
4.3
通讯作者：
Wainberg, Zev A.
中科院分区：
文献类型：
--
作者：
Reddy, Deepa;Wainberg, Zev A.
转移性食管胃肿瘤(EGC)患者的预后和长期生存较差。从历史上看，主要的治疗方法是联合化疗。最近，一些靶向治疗已经开发并正在研究中，目的是提高转移性EGC患者的应答率和存活率。到目前为止，唯一获得临床批准的靶向治疗是以HER2/Neu癌基因为靶点的曲妥珠单抗。然而，只有一小部分EGCs患者的HER2基因被扩增，目前正在研究的还有其他重要的靶点/途径在这些癌症的发展中发挥作用。随着这些其他临床相关途径的确定，预计未来还将批准其他几种治疗方法。
The prognosis and long-term survival for patients with metastatic esophagogastric cancer (EGC) is poor. Historically, the mainstay of treatment has been combination chemotherapy. More recently, a number of targeted therapies have been developed and are being studied with the goal of improving response rate and survival in patients with metastatic EGC. To date, the only targeted therapy which has been clinically approved is trastuzumab which targets the HER2/Neu oncogene. However, only a small group of patients with EGCs are HER2 amplified, and there are other important targets/pathways which play a role in the development of these cancers that are currently being studied. With the identification of these other clinically relevant pathways, it is anticipated that several other therapies will be approved in the future.